An Antagonist of AMPA/Kainate Receptors
Cat #: N-185
  • Lyophilized Powder
  • Bioassay Tested
  • Source Synthetic
    MW: 336.3
    Purity: >99%
    Effective concentration 0.1-500 µM.
    Chemical name 2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide.
    Molecular formula C12H8N4O6S.
    CAS No.: 118876-58-7.
    Activity NBQX in a potent inhibitor of non NMDA glutamate receptor channels exhibiting IC50s of 0.1-0.4 μM for AMPA and 1.7-8 μM for Kainate receptors1.
    Shipping and storage Shipped at room temperature. Product as supplied can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.
    Solubility DMSO. Centrifuge all product preparations before use (10000 x g 5 min).
    Storage of solutions Up to four weeks at 4°C or three months at -20°C.
      • Alomone Labs NBQX inhibits GluA1 channels expressed in Xenopus oocytes.
        Representative time course of GluA1 current, activated by a continuous application (top dotted line) of 5 µM (S)-AMPA (#A-267), and reversibly inhibited by 1 µM and 5 µM NBQX (#N-185), as indicated (horizontal bars), at a holding potential of -60 mV.
      • The α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA receptor) is a non-N-methyl-D-aspartate (non-NMDA) type ionotropic transmembrane receptor for glutamate that mediates fast synaptic transmission in the central nervous system (CNS). AMPA receptors normally assemble from four genetically distinct subunits: GluR1, GluR2, GluR3, and GluR4, which combine to form receptor complexes with different functional properties1.

        NBQX (2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F) quinoxaline) is an analogue of the quinoxalinedione antagonists to the non-NMDA glutamate receptor. NBQX is a potent and selective inhibitor of binding to the quisqualate subtype of the glutamate receptor, with no activity at the NMDA and glycine site2. It is a specific and potent AMPA receptor antagonist and has been found to be neuroprotective in various models of ischemia and to have anticonvulsant properties in different models of epilepsy3. NBQX has been reported to block the excitatory actions of AMPA in rat neocortex slices while having no effect on NMDA responses4. It was also reported to selectively block AMPA-induced depolarizations but not spontaneous epileptiform discharges in Mg2+ free medium in the rat cortical wedge5. NBQX blocks AMPA and Kainate receptors at micromolar concentrations6,7.

    Target AMPA/Kainate receptors
    Last update: 11/03/2019

    NBQX (#N-185) is a highly pure, synthetic, and biologically active compound.

    For research purposes only, not for human use